MedPath
Found 18 clinical trials|View Analysis
Sort by:

Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

Phase 1
Recruiting
Conditions
Smoking Cessation
Interventions
First Posted Date
2024-04-18
Last Posted Date
2024-05-16
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
20
Registration Number
NCT06374290
Locations
🇺🇸

The University of Texas health Science Center at Houston, Houston, Texas, United States

Open Label Comparison of Injectable Buprenorphine ( Brixadi®) and Naltrexone (Vivitrol®) for Opioid Use Disorder

Phase 2
Recruiting
Conditions
Opioid Use Disorder
Interventions
First Posted Date
2022-10-27
Last Posted Date
2024-02-23
Lead Sponsor
University of Pennsylvania
Target Recruit Count
60
Registration Number
NCT05596955
Locations
🇺🇸

Addiction Treatment Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Vivitrol Treatment for Cannabis Use Disorder

Phase 2
Conditions
Cannabis Use Disorder
Interventions
Drug: Naltrexone 380 MG [Vivitrol]
Behavioral: Motivational Enhancement Therapy and Cognitive Behavioral Therapy
First Posted Date
2019-10-25
Last Posted Date
2020-09-25
Lead Sponsor
Centre for Addiction and Mental Health
Target Recruit Count
10
Registration Number
NCT04139668
Locations
🇨🇦

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

Phase 3
Completed
Conditions
Methamphetamine Use Disorder
Interventions
Drug: Placebo (PLB) Injectable
Drug: Placebo (PLB) Oral
First Posted Date
2017-03-13
Last Posted Date
2021-05-03
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
403
Registration Number
NCT03078075
Locations
🇺🇸

University of California Los Angeles (UCLA) Center for Behavioral Addiction Medicine (CBAM), Los Angeles, California, United States

🇺🇸

Substance Use Research Unit (SURU) at the San Francisco Dept. of Public Health, San Francisco, California, United States

🇺🇸

Hennepin County Medical Center- Berman Center for Research, Minneapolis, Minnesota, United States

and more 5 locations

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings

Phase 4
Completed
Conditions
Opioid-Related Disorders
Interventions
First Posted Date
2016-12-01
Last Posted Date
2020-06-16
Lead Sponsor
Duke University
Target Recruit Count
14
Registration Number
NCT02978417
Locations
🇺🇸

Fellowship Health Resources (FHR), Raleigh, North Carolina, United States

ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids

Phase 2
Completed
Conditions
Opiate Dependence
Interventions
Drug: Medisorb naltrexone 75 mg
Drug: Medisorb naltrexone 150 mg
Drug: Medisorb naltrexone 300 mg
Drug: Hydromorphone (10 mg/mL)
Drug: Naloxone Challenge and Oral Naltrexone Tolerability Testing
First Posted Date
2010-10-13
Last Posted Date
2017-01-11
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
27
Registration Number
NCT01218984

ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)

Phase 3
Completed
Conditions
Alcohol Dependence
Interventions
Drug: Medisorb naltrexone 380 mg
Drug: Medisorb naltrexone 190 mg
First Posted Date
2010-10-13
Last Posted Date
2010-12-24
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
332
Registration Number
NCT01218971

ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults

Phase 3
Completed
Conditions
Alcoholism
Interventions
Drug: Placebo matching Medisorb naltrexone 190 mg
Drug: Placebo matching Medisorb naltrexone 380 mg
Drug: Medisorb naltrexone 190 mg
Drug: Medisorb naltrexone 380 mg
First Posted Date
2010-10-13
Last Posted Date
2017-07-11
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
624
Registration Number
NCT01218958

ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

Phase 3
Completed
Conditions
Alcoholism
Interventions
First Posted Date
2010-10-13
Last Posted Date
2011-01-04
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
436
Registration Number
NCT01218997

ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

Phase 3
Completed
Conditions
Opiate Dependence
Interventions
First Posted Date
2009-02-03
Last Posted Date
2018-12-11
Lead Sponsor
Alkermes, Inc.
Target Recruit Count
38
Registration Number
NCT00834080
Locations
🇺🇸

Alkermes Clinical Study Site, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath